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Background. There is limited information on the association between colonization density of upper respiratory tract colonizers 
and pathogen-specific pneumonia. We assessed this association for Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus 
aureus, and Pneumocystis jirovecii.
Methods. In 7 low- and middle-income countries, nasopharyngeal/oropharyngeal swabs from children with severe pneumonia 
and age-frequency matched community controls were tested using quantitative polymerase chain reaction (PCR). Differences in 
median colonization density were evaluated using the Wilcoxon rank-sum test. Density cutoffs were determined using receiver oper-
ating characteristic curves. Cases with a pathogen identified from lung aspirate culture or PCR, pleural fluid culture or PCR, blood 
culture, and immunofluorescence for P. jirovecii defined microbiologically confirmed cases for the given pathogens.
Results. Higher densities of H.  influenzae were observed in both microbiologically confirmed cases and chest radiograph 
(CXR)–positive cases compared to controls. Staphylococcus aureus and P.  jirovecii had higher densities in CXR-positive cases vs 
controls. A 5.9 log10 copies/mL density cutoff for H. influenzae yielded 86% sensitivity and 77% specificity for detecting microbio-
logically confirmed cases; however, densities overlapped between cases and controls and positive predictive values were poor (<3%). 
Informative density cutoffs were not found for S. aureus and M. catarrhalis, and a lack of confirmed case data limited the cutoff 
identification for P. jirovecii.
Conclusions. There is evidence for an association between H. influenzae colonization density and H. influenzae–confirmed pneu-
monia in children; the association may be particularly informative in epidemiologic studies. Colonization densities of M. catarrhalis, 
S. aureus, and P. jirovecii are unlikely to be of diagnostic value in clinical settings.
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Many pneumonia pathogens can also be upper respiratory 
tract (URT) colonizers, including Streptococcus pneumoniae, 
Haemophilus influenzae, Staphylococcus aureus, Moraxella 
catarrhalis, and Pneumocystis jirovecii [1–6]. Obtaining speci-
mens from the site of infection remains challenging, as direct 
lung aspiration is rarely done, and blood cultures are insen-
sitive and often unavailable in areas of highest pneumonia 
burden [7, 8]. In many settings, the high frequency of URT 
colonization with these potential pathogens in healthy chil-
dren undermines the application of qualitative diagnostic 
tests, such as polymerase chain reaction (PCR), to ascribe eti-
ology [9].
Previous studies have suggested that children with pneumo-
nia may have higher pathogen density in the URT compared to 
children without pneumonia, though there is heterogeneity by 
study and pathogen [1, 4, 10–19]. We set out to determine if den-
sity of URT colonizers predicted pathogen-specific infections 
among pneumonia cases in the Pneumonia Etiology Research 
for Child Health (PERCH) study. Provided differences in densi-
ties between cases and controls, we evaluated whether pathogen 
densities offer any value in pneumonia diagnostic algorithms, or 
provide information beyond presence or absence of positivity 
alone in analytic models such as the PERCH integrated analysis 
[20]. The density evaluation for S. pneumoniae is reported else-
where [21].
METHODS
The PERCH study is a multicountry, standardized evalua-
tion of the etiologic agents causing severe and very severe 
pneumonia among children in sites in 7 low- and middle-in-
come countries: Dhaka and Matlab, Bangladesh; Basse, The 
Gambia; Kilifi, Kenya; Bamako, Mali; Soweto, South Africa; 
Nakhon Phanom and Sa Kaeo, Thailand; and Lusaka, Zambia. 
Haemophilus influenzae type b vaccine was used routinely at all 
sites except Thailand, while South Africa, The Gambia, Mali, 
and Kenya used pneumococcal conjugate vaccine throughout 
the duration of the study [22]. PERCH followed a standardized 
protocol for enrollment, specimen collection, and laboratory 
testing [23].
Case and Community Control Selection and Clinical Evaluation
Identification and selection of cases and controls have been 
described previously [24]. In brief, we enrolled hospitalized 
patients aged 1– 59  months with World Health Organization 
(WHO)–defined severe or very severe pneumonia and age-fre-
quency matched community controls. Severe pneumonia was 
defined as having cough or difficulty breathing and lower chest 
wall indrawing; very severe pneumonia was defined as cough or 
difficulty breathing and at least 1 of the following: central cya-
nosis, difficulty breastfeeding/drinking, vomiting everything, 
convulsions, lethargy, unconsciousness, or head nodding [25]. 
Within this case definition we further defined radiographic 
pneumonia as consolidation or any other infiltrate on chest radi-
ograph (CXR positive) as interpreted by a panel of trained CXR 
readers [26, 27]. Microbiologically confirmed cases were those 
with identification of the respective pathogen by PCR from lung 
aspirate or pleural fluid; bacterial culture from lung aspirate, pleu-
ral fluid, or blood; or P. jirovecii by induced sputum, pleural fluid, 
or lung aspirate immunofluorescence or toluidine blue staining 
[28]. Antibiotic pretreatment was defined by having either posi-
tive serum bioassay or clinician report of antibiotics administered 
prior to specimen collection on the day of admission.
Specimen Collection
A flocked nasopharyngeal (NP) swab (flexible minitip, Copan) 
and a rayon oropharyngeal (OP) swab (Fisher Scientific), trans-
ported in universal transport media (Copan) and processed 
within 24 hours of collection were used for URT pathogen 
detection by PCR. Blood was collected for culture. Pleural fluid 
specimens were collected as clinically indicated. Lung aspirates 
were collected from a subset of cases in The Gambia, South 
Africa, Mali, and Bangladesh.
Laboratory Testing
PERCH employed conventional and molecular diagnostic tech-
niques for the identification of potential pathogens, as described 
elsewhere [8, 28–31]. In brief, total nucleic acid extraction was 
performed on respiratory specimens using the NucliSens easy-
MAG system (bioMérieux, Marcy l’Etoile, France). Four hun-
dred microliters of each respiratory specimen was eluted to a 
final volume of 60–110 μL nucleic acid.
Respiratory specimens (including lung aspirate and pleural 
fluid specimens) were evaluated using the Fast Track Diagnostics 
Respiratory Pathogens 33 test (FTD Resp-33) (Fast-track 
Diagnostics, Sliema, Malta), a 33-target, 8-multiplex real-time 
quantitative PCR platform for the detection of selected viruses 
and the following bacteria and fungi: P. jirovecii; Mycoplasma 
pneumoniae; Chlamydophila pneumoniae; S. pneumoniae; H. 
influenzae type b; H. influenzae species; S. aureus; M. catarrh-
alis; Bordetella pertussis; Klebsiella pneumoniae; and Salmonella 
species. Standard curves for quantification were generated using 
10-fold serial dilutions of plasmid standards provided by FTD 
approximately every 3 months and were used to calculate path-
ogen density (log10 copies/mL) from the sample cycle threshold 
values; standards were only available for the linear range of detec-
tion of the assay from 4.0 to 8.0 log10 copies/mL. Additionally, 
induced sputum, pleural fluid, and lung aspirate specimens were 
tested for P. jirovecii by immunofluorescence (South Africa) and 
toluidine blue staining (Zambia).
Blood cultures were incubated using automated systems 
(BacT/ALERT in South Africa, Thailand, and Bangladesh; 
BACTEC at all other sites). Organisms were identified accord-
ing to standard microbiological methods.
Downloaded from https://academic.oup.com/cid/article-abstract/64/suppl_3/S328/3858223
by London School of Hygiene & Tropical Medicine user
on 15 January 2018
S330 • CID 2017:64 (Suppl 3) • Park et al
Statistical Analysis
We made comparisons between community controls and both 
microbiologically confirmed pneumonia cases and radio-
graphic pneumonia cases. Microbiologically confirmed cases 
were not restricted to children with abnormal findings on CXR 
in order to include children who died before a radiograph was 
taken or had not developed a positive finding at time of initial 
radiograph. Human immunodeficiency virus (HIV)–infected 
cases were included in a supplemental analysis for P.  jirovecii 
but excluded from all other analyses.
Among children positive for each organism, mean and 
median colonization densities were compared using Wilcoxon 
rank-sum tests. Potential covariates of colonization density 
were evaluated, including site, age, sex, vaccination status, and 
prior antibiotic administration [32]. Total bacterial load (across 
all bacteria tested for by FTD Resp-33) was compared between 
cases and controls, in addition to proportional pathogen den-
sities comparing proportional contributions of a given organ-
ism to the total bacterial load. Receiver operating characteristic 
(ROC) curves and the corresponding area under the curve 
(AUC) were generated to investigate the performance of abso-
lute density in determining case status among microbiologically 
confirmed cases and community controls including children 
without detection of the given pathogen in the URT by PCR, and 
also between radiographic pneumonia cases and community 
controls positive for each organism in the URT by PCR. The 
Youden index was calculated to determine the best-performing 
cutoffs to differentiate cases and community controls [33]. To 
guard against bias in the estimates of sensitivity due to having 
a small number of confirmed cases for each potential patho-
gen, the Youden index was calculated using leave-one-out 
cross-validation when sample sizes were sufficient [34]. Positive 
and negative predictive values associated with each cutoff were 
calculated comparing microbiologically confirmed cases as the 
gold standard against all HIV-uninfected cases.
All analyses were performed using SAS software version 9.4 
(SAS Institute, Cary, North Carolina) and R Statistical Software 
3.2.1 (R Foundation for Statistical Computing, Vienna, Austria). 
P values are 2 sided.
Ethical Considerations
The PERCH study protocol was approved by the institutional 
review board or ethical review committee at each of the study 
site institutions and at the Johns Hopkins Bloomberg School of 
Public Health. Parents or guardians of all participants provided 
written informed consent.
RESULTS
Of the 4232 cases enrolled in the PERCH study, 4139 cases had 
available NP/OP PCR results; of those, 239 additional cases 
Table 1. Characteristics of Children Included in Analysis of Quantificationa
Characteristic
Microbiologically Confirmed Casesb 
(n = 52)
CXR-Positive Casesc 
(n = 1700)
Controls  
(n = 4986)
Site Kenya 4 (7.7) 278 (16.4) 855 (17.1)
The Gambia 8 (15.4) 267 (15.7) 624 (12.5)
Mali 14 (26.9) 229 (13.5) 724 (14.5)
Zambia 11 (21.2) 185 (10.9) 535 (10.7)
South Africa 13 (25.0) 425 (25.0) 823 (16.5)
Thailand 2 (3.8) 97 (5.7) 657 (13.2)
Bangladesh 0 (0) 219 (12.8) 768 (15.4)
Age 1-5 mo 24 (46.2) 667 (39.2) 1555 (31.2)
6-11 mo 11 (21.2) 409 (24.1) 1187 (23.8)
12-23 mo 11 (21.2) 414 (24.4) 1235 (24.8)
24-59 mo 6 (11.5) 210 (12.4) 1009 (20.2)
Sex Female 32 (61.5) 736 (43.3) 2477 (49.7)
Antibioticsd Prior to NP/OP swab collection 22 (42.3) 791 (46.5) 84 (1.7)
No. of bacteria detectede 0 … 75 (4.4) 141 (2.8)
1 2 (3.8) 197 (11.6) 486 (9.7)
2 9 (17.3) 376 (22.1) 1141 (22.9)
≥3 40 (76.9) 1033 (60.8) 3195 (64.1)
P value <.05 for case-control group comparisons of overall site, overall age, sex, prior antibiotics, and number of bacteria detected, obtained from χ2 test.
Data are presented as No. (%).
Abbreviations: CXR, chest radiograph; NP/OP, nasopharyngeal/oropharyngeal.
aChildren with available NP/OP polymerase chain reaction results.
bMicrobiologically confirmed for Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, or Pneumocystis jirovecii.
cCXR positive defined as having radiographic evidence of pneumonia (consolidation and/or other infiltrate), excluding microbiologically confirmed cases of H.  influenzae, M. catarrhalis, 
S. aureus, or P. jirovecii.
dAdministered antibiotics at the study facility prior to the collection of specimens (cases only), positive serum bioassay (cases and controls), received antibiotics at a referral facility (cases 
only), or received routine cotrimoxazole prophylaxis (cases and controls).
eIncluding Bordetella pertussis, Chlamydophila pneumoniae, H. influenzae, M. catarrhalis, Mycoplasma pneumoniae, P. jirovecii, S. aureus, Salmonella species, and Streptococcus pneumoniae.
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were excluded for being HIV infected, resulting in 3900 cases. 
Among the 3900 cases, 52 (1.3%) were microbiologically con-
firmed for at least 1 organism of interest, 1733 (44.4%) had an 
abnormal CXR, and 1700 (43.6%) had an abnormal CXR with-
out microbiologic confirmation of H. influenzae, M. catarrhalis, 
S.  aureus, or P.  jirovecii (Table  1). Site sample sizes for CXR-
positive cases varied from 425 cases in South Africa to 97 cases 
in Thailand. From 5118 enrolled HIV-negative controls, 4986 
(97.4%) had available NP/OP PCR results. Compared to con-
trols, cases tended to be younger and were more likely to have 
had antibiotics prior to their NP/OP sample collection.
Prevalence and Density Comparisons Between Microbiologically 
Confirmed Cases, Radiographic Pneumonia Cases, and Community Controls
All 21 cases with microbiologically confirmed H. influenzae (8 
type b, 9 nontypeable, 2 type a, 2 unknown) were NP/OP posi-
tive for H. influenzae. Among the 21 cases, 14 (66.7%) were CXR 
positive. Six confirmed M. catarrhalis cases were NP/OP pos-
itive, among which 4 (66.7%) were CXR positive. Fifteen con-
firmed S. aureus cases were NP/OP positive, among which 10 
(66.7%) were CXR positive. One confirmed P. jirovecii case was 
NP/OP positive and was also CXR positive. Only H. influenzae 
was found at significantly higher median densities in microbio-
logically confirmed cases compared to controls (Table 2).
Comparing non–microbiologically confirmed CXR-positive 
cases to controls, H. influenzae was more commonly detected in the 
NP/OP of cases vs controls (57.3% vs 51.5%, P < .001). Prevalence 
was similar between CXR-positive cases and controls for S. aureus 
and P. jirovecii. Moraxella catarrhalis detection was more common 
among controls than CXR-positive cases, even after adjusting for 
site and prior antibiotics (65.8% vs 74.3%, P ≤ .001). Median den-
sity (log10 copies/mL) was higher in CXR-positive cases compared 
to controls for H. influenzae, S. aureus, and P. jirovecii, while M. 
catarrhalis median density was similar in CXR-positive cases and 
controls. For all organisms, there was substantial overlap of the dis-
tribution of densities between microbiologically confirmed cases, 
CXR-positive cases, and controls (Figure 1).
Though densities varied by site, trends between microbi-
ologically confirmed cases, CXR-positive cases, and controls 
remained and were consistent across age categories, WHO-
defined severity categories, and sex (Supplementary Figure 2). 
Prior antibiotic use was associated with a lower density for 
H.  influenzae (6.15 vs 5.64 log10 copies/mL) and M.  catarrh-
alis (5.77 vs 5.21 log10 copies/mL) among CXR-positive cases 
(Supplementary Figure 3). There were similar rates of antibiotic 
use prior to NP/OP specimen collection between microbiologi-
cally confirmed cases and nonconfirmed CXR-positive cases. 
HIV-infected, CXR-positive cases had a higher median density 
compared to HIV-negative, CXR-positive cases for P.  jirovecii 
(5.03 vs 3.78 log10 copies/mL) (Supplementary Figure 4).
Total and Proportional Bacterial Density
Total bacterial density across all bacterial targets from our PCR 
panel was similar among consolidated pneumonia cases (5.90 
log10 copies/mL), CXR-positive cases (5.81 log10 copies/mL), and 
controls (5.75 log10 copies/mL), and also similar among CXR-
positive cases across age groups, adjusting for prior antibiotic 
use and site. Evaluating whether the proportion of total bacterial 
density attributable to specific organisms differed between case 
and control groups, median relative proportions of H. influenzae 
Table 2. Detection Prevalence and Median Pathogen Density (Copies/mL) From Nasopharyngeal/Oropharyngeal Swabs for Microbiologically Confirmed 
Cases, Non–Microbiologically Confirmed Radiographic Pneumonia Cases, Cases Microbiologically Confirmed for Another Pathogen, and Controls— 
All Sites
A. Confirmed 
Casesa
B. CXR-Positive 
Cases (n = 1657)
C. Cases Confirmed for 
Other Pathogenb
D. All Controls 
(n = 4986)
Difference in Median 
Densities, P Valuec
Colonizer Measure A vs C A vs D B vs D
Haemophilus 
influenzae
NP/OP+, No. (%)d 21/21 (100) 949 (57.3) 76/121 (62.8) 2562 (51.5)
Median density (IQR)e 6.77 (6.00–7.12) 5.90 (5.00–6.66) 6.39 (5.53–7.08) 5.71 (4.89–6.35) .19 <.001 <.001
Moraxella 
catarrhalis
NP/OP+, No. (%)d 6/7 (85.7) 1091 (65.8) 92/135 (68.1) 3694 (74.3)
Median density (IQR)f 6.01 (5.00–6.73) 5.50 (4.65–6.26) 6.15 (5.09–6.78) 5.59 (4.87–6.20) .88 .44 .07
Pneumocystis 
jirovecii
NP/OP+, No. (%)d 1/2 (50.0) 149 (9.0) 10/140 (7.1) 382 (7.7)
Median density (IQR)f 4.01 (NA) 3.92 (3.08–4.73) 4.00 (2.14–5.95) 3.56 (3.02–4.10) … .44 <.001
Staphylococcus 
aureus
NP/OP+, No. (%)d 15/23 (65.2) 342 (20.6) 29/119 (24.5) 940 (18.9)
Median density (IQR)f 4.87 (3.87–5.64) 4.48 (3.43–5.53) 5.14 (4.46–5.85) 4.29 (3.42–5.17) .43 .13 .05
Abbreviations: CXR, chest radiograph; IQR, interquartile range; NA, not applicable; NP/OP, nasopharyngeal/oropharyngeal.
aDetection of relevant pathogen from blood culture, lung aspirate culture/polymerase chain reaction (PCR), pleural fluid culture/PCR, pneumocystis immunofluorescence or staining.
bMicrobiologically confirmed case for any other bacteria or virus.
cComparing median densities using Wilcoxon rank-sum test.
dNo. (%) positive in the NP/OP for organism among those with available results for that target.
eLog10 copies/mL, among all confirmed case positives including NP/OP PCR negatives counted as zero densities.
fAmong those positive on NP/OP PCR.
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tended to be higher in H. influenzae–confirmed cases (41.6%) 
and CXR-positive cases (7.2%) compared with controls (1.2%). 
Conversely, median proportional densities of M.  catarrhalis 
were higher in controls compared to CXR-positive cases (14.3% 
vs 5.0%). Among 100 randomly selected controls, 24% had 
M. catarrhalis–dominated proportional densities (≥50%) com-
pared with 14%–16% of non–M.  catarrhalis confirmed cases 
(Supplementary Figure 6). However, there was substantial over-
lap in the range of proportional densities between microbiologi-
cally confirmed cases, CXR-positive cases, and controls.
Determination of Density Cutoffs
Using density in log10 copies/mL in microbiologically confirmed 
cases compared to controls, the ROC curve best-performing 
cutoff of 5.9 log10 copies/mL was identified for H. influenzae 
with a sensitivity of 86% and specificity of 77% (Figure 2 and 
Table 3). Though the S. aureus cutoff (3.0 log10 copies/mL) was 
moderately sensitive and specific, the S. aureus cutoff did not 
significantly improve sensitivity and specificity over qualitative 
analysis using simply presence or absence of specific organisms.
Given the limited numbers of NP/OP-positive microbiologi-
cally confirmed P.  jirovecii (n = 1) and M. catarrhalis (n = 6) 
cases, we explored the use of NP/OP positive, CXR-positive 
cases and controls to identify potential cutoffs for P.  jirovecii 
(4.0 log10 copies/mL) and M. catarrhalis (5.0 log10 copies/mL) 
(Supplementary Figure 5). Densities among the limited number 
of microbiologically confirmed cases were consistent with these 
cutoffs, as 5 of 6 microbiologically confirmed M.  catarrhalis 
cases were above the thresholds. The P. jirovecii cutoff demon-
strated 48% sensitivity and 72% specificity for identifying 
P.  jirovecii–positive CXR-positive cases (AUC  =  0.58), among 
cases and controls positive for P.  jirovecii (98% specificity 
Figure 1. Median density in the nasopharynx/oropharynx (NP/OP) among microbiologically confirmed cases, radiographic pneumonia (chest radiograph positive [CXR+]) 
casesa, and controls, restricted to participants testing NP/OP positive for the given pathogen. Horizontal lines through boxes indicate group medians. Boxes extend to the 25th 
and 75th percentiles. Whiskers extend to minimum and maximum. aDefined as having radiographic evidence of pneumonia (consolidation and/or other infiltrate), excluding 
confirmed cases.
Table 3. Receiver Operating Characteristic Curve Nasopharyngeal/Oropharyngeal Cutoffsa for Determining Case Status and Corresponding Area Under 
the Curve, Positive Proportion in Cases, and Negative Proportion in Controls by Pathogen
Confirmed Cases vs Controls NP/OP-Positive, CXR-Positive Casesb vs Controls
Colonizer
Best-Performing 
Cutoff (Log10 
Copies/mL) AUC
Proportion of 
Cases Above 
Cutoff
Proportion of 
Controls Below 
Cutoff
Best-Performing  
Cutoff (Log10  
Copies/mL) AUC
Proportion of 
Positive Cases 
Above Cutoff
Proportion of 
Positive Controls 
Below Cutoff
Haemophilus 
influenzae
5.92 0.87 0.86 0.77 … … … …
Moraxella 
catarrhalis
… … … … 4.99 0.50 0.34 0.71
Pneumocystis 
jirovecii
… … … … 4.01 0.58 0.48 0.72
Staphylococcus 
aureus
2.97 0.6 0.65 0.84 … … … …
Abbreviations: AUC, area under the curve; CXR, chest radiograph; NP/OP, nasopharyngeal/oropharyngeal.
aCutoffs for confirmed cases calculated using the Youden index for H. influenzae, and S.aureus (with cross-validation). Confirmed cases defined as any detection from blood culture, lung 
aspirate culture/polymerase chain reaction (PCR), or pleural fluid culture/PCR. Cutoffs for CXR-positive cases calculated using the Youden index (with cross-validation) comparing CXR-positive 
cases to controls, excluding children who were negative by NP/OP PCR.
bDefined as having radiographic evidence of pneumonia (consolidation and/or other infiltrate).
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including negatives). Moraxella catarrhalis cutoffs did not help 
differentiate CXR-positive cases from controls (AUC = 0.50).
Positive and Negative Predictive Values Using Dichotomous Positivity and 
Density Cutoffs
Positive predictive values (PPVs) for identifying microbiologi-
cally confirmed cases from all cases using dichotomous URT 
positivity were low and improved marginally when density cut-
offs were applied to H. influenzae (1.01% to 1.75%), S. aureus 
(1.81% to 2.14%), and P. jirovecii (0.89% to 1.67%), though the 
PPV is limited by lack of sensitivity in identifying microbiologi-
cally confirmed cases. Conversely, negative predictive values for 
identifying H. influenzae, S. aureus, and P. jirovecii microbio-
logically confirmed cases remained >99% for any detection in 
the URT and when utilizing the density cutoff.
Clinical Characteristics Associated With Being Above Versus Below 
Optimized Cutoffs
Densities above the cutoffs (compared to low densities and neg-
atives) were associated with hypoxemia (adjusted odds ratio 
[AOR],  1.22; 95% confidence interval [CI],  1.02–1.47), any 
CXR abnormality (AOR, 1.23; 95% CI, 1.05–1.45), and primary 
endpoint consolidation (AOR,  1.57; 95% CI,  1.28–1.92) for 
H. influenzae, adjusted for site, age, sex, and prior antibiotic use. 
Additionally, having a density above the cutoff was associated 
with case fatality for P. jirovecii (AOR, 4.5; 95% CI, 2.6–7.5).
DISCUSSION
Colonization density of the URT with H. influenzae was signif-
icantly higher in microbiologically confirmed cases compared 
with community controls. Given the high prevalence of H. influ-
enzae as a common colonizer, the improved specificity provided 
by the optimized cutoff of 5.9 log10 copies/mL helped delineate 
between common colonization and H.  influenzae–mediated 
pneumonia. However, the overlapping density distributions 
between all case and control groups, and the low PPV limit 
the utility of density in individuals for clinical diagnosis. Our 
findings are similar to results from a study in adult patients in 
Denmark that yielded 90% sensitivity and 65% specificity using 
a cutoff at 5.0 log copies/mL [17]. Another study in Vietnamese 
children did not find an association between NP H. influenzae 
density and radiographic pneumonia; however, findings may 
have been limited by lack of a confirmed case group [12].
Colonization density of P.  jirovecii may provide informa-
tion toward differentiating carriage and pathogen-mediated 
pneumonia, although our evaluation was limited by a lack of 
microbiologically confirmed pneumocystis pneumonia (PCP) 
cases. A potential cutoff at 4.0 log10 copies/mL conferred 50% 
sensitivity and 72% specificity for radiographic pneumonia; 
however, the proportion of radiographic pneumonia cases with 
PCP-mediated pneumonia is unknown, and the PERCH pro-
cess for identifying CXR abnormality may have been less sen-
sitive for detecting radiographic features uniquely associated 
with PCP. The potential density cutoff is in line with other stud-
ies that have identified cutoffs between approximately 3 and 4.5 
log copies/mL using clinically confirmed PCP patients, though 
we have not standardized the quantitative standards across 
these different studies [14–16]. Utilizing P.  jirovecii detection 
from induced sputum PCR is widely accepted in clinical prac-
tice and would have expanded our sample of microbiologically 
Figure 2. Receiver operating characteristic (ROC) curve and Youden index analysis for Haemophilus influenzae and Staphylococcus aureus confirmed cases compared with 
controls.
Downloaded from https://academic.oup.com/cid/article-abstract/64/suppl_3/S328/3858223
by London School of Hygiene & Tropical Medicine user
on 15 January 2018
S334 • CID 2017:64 (Suppl 3) • Park et al
confirmed cases [35, 36]. However, these diagnostic tests are 
typically carried out when pneumocystis pneumonia is clin-
ically suspected; findings from the PERCH study complicate 
the utility of induced sputum PCR as a confirmatory diagnostic 
tool in settings where nearly all cases had an induced sputum 
specimen collected [37].
Previous studies have failed to identify an association between 
density and pathogen-confirmed pneumonia for M. catarrhalis 
and S. aureus [1]. While the optimized S. aureus cutoff was spe-
cific, the relatively high proportion of NP/OP negatives among 
the microbiologically confirmed cases precludes the iden-
tification of a highly sensitive and specific cutoff. It has been 
suggested that Moraxella and Corynebacterium/Dolosigranulum-
dominated microbiota profiles confer stability and are pro-
tective against respiratory disease, while Streptococcus- and 
Haemophilus-dominated microbiota profiles enhance suscepti-
bility to respiratory infections [38, 39]. The protective effect of 
M. catarrhalis is supported by our finding of both higher prev-
alence, proportional density, and absolute density in controls 
compared to radiographic pneumonia cases.
Though our analysis benefited from a large sample size enrolled 
from multiple heterogeneous study sites and comprehensive 
clinical and laboratory standardization, there were limitations. 
Despite our large overall sample size, the number of microbio-
logically confirmed cases was limited. However, leave-one-out 
cross validation and findings from comparisons of CXR-positive 
cases vs controls supported findings from microbiologically con-
firmed cases. While we were able to evaluate co-pathogen inter-
actions and proportional densities between a select number of 
potential pathogens, a metagenomics or microbiome approach 
would be better suited to understand the contribution of indi-
vidual pathogens in the context of the upper respiratory tract 
microbiome [40–45]. Furthermore, we were unable to establish 
temporality between higher densities in the NP/OP and subse-
quent development of pneumonia, as infection in the lung may 
lead to higher densities in the NP/OP. Longitudinal studies would 
be better suited to addressing the role of colonization density on 
the development of pneumonia. The study design did not control 
for prior antibiotic use, which was associated with lower densities 
for both H. influenzae and M. catarrhalis. However, because prior 
antibiotic use was more common among cases compared to con-
trols, the bias was toward the null for the analyses. Staphylococcus 
aureus and P. jirovecii are unlikely to be significantly affected by 
first-line antibiotics, which was reflected in our findings [46]. 
Variability of density distributions by site was also observed; 
however, density trends between the microbiologically con-
firmed case, radiographic pneumonia case, and control groups 
within a site followed the overall trends.
While we have provided cutoffs optimized for sensitivity and 
specificity, the choice of a cutoff can be tailored for specific appli-
cations. Identifying a density cutoff that maximizes combined 
sensitivity and specificity provides additional information from 
the NP/OP specimen in the PERCH primary etiology analy-
sis; however, the interpretation and application of these cutoffs 
may not be ideal for use as either a diagnostic or screening tool 
(which may prioritize specificity and sensitivity, respectively). 
Moreover, the PPV using the density cutoff remained low for 
H. influenzae, although the PPV was limited by poor sensitiv-
ity for identifying microbiologically confirmed cases and low 
prevalence. Regardless, it is likely impossible to identify a URT 
density cutoff for these colonizers that could be applied as a 
clinical gold standard because the densities overlap and span 
the PCR linear range in both cases and controls, precluding the 
identification of clear cutoffs that would independently guide 
clinical decisions.
We found evidence for the relationship between H. influenzae 
colonization density and H.  influenzae–mediated pneumonia 
in children, and also a potential association between P. jirovecii 
colonization density and pathogen-specific pneumonia. The use 
of molecular diagnostics from URT specimens provides signif-
icant advantages in both sensitivity and speed over traditional 
culture diagnostics, but ascribing lung infection based on detec-
tion of colonization in the URT is challenging. Compared to 
using presence or absence of positivity, utilizing colonization 
density improves specificity of molecular diagnostics with small 
reductions in sensitivity and improves information from the 
URT in the context of population-level epidemiologic studies 
such as the PERCH integrated analysis, but remains suboptimal 
for use as a gold standard diagnostic in clinical settings at the 
individual case level.
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